Neil Rabin

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

Meletios Α. Dimopoulos, Albert Oriol, Hareth Nahi et al. · New England Journal of Medicine · 2016 · 1.4K citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 385 citations · Full text

Medicine, Hematology, Pharmacotherapy +11

Factors that influence short-term homing of human bone marrow-derived mesenchymal stem cells in a xenogeneic animal model

Chara Kyriakou, Neil Rabin, Arnold Pizzey et al. · Haematologica · 2008 · 129 citations · Full text

Life Sciences, Cell Biology, Cell Therapy +15

Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial

Meletios Α. Dimopoulos, Albert Oriol, Hareth Nahi et al. · Journal of Clinical Oncology · 2023 · 128 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib induction

Arash Latifoltojar, Margaret Hall‐Craggs, Alan Bainbridge et al. · European Radiology · 2017 · 76 citations · Full text

Medicine, Oncology, Radiology +15